UBS Group
BPMC

UBS Group’s Blueprint Medicines BPMC Stock Holding History

UBS Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-112,000
Closed -$7.11M – 7987
2018
Q2 		$7.11M Buy
+112,000
New +$8.91M ﹤0.01% 2032

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's BPMC Position: Q3 2025 in Review

UBS Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 2,167,028 shares — an estimated $278M sold.

UBS Group first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $278M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • UBS Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 2,167,028 Blueprint Medicines shares in Q3 2025, an estimated $278M.
  • UBS Group first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
  • UBS Group's Blueprint Medicines position peaked at $278M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.